Smallets Sarah, Litvin Sydney, Abele Grayson, Kirsh Sarah, Paustenbach Dennis
TRC Companies, Inc., Denver, CO, United States.
TRC Companies, Inc., Jackson, WY, United States.
Front Pharmacol. 2025 Aug 29;16:1620601. doi: 10.3389/fphar.2025.1620601. eCollection 2025.
, commonly known as kratom, has gained popularity in the United States due to its stimulant and analgesic effects. Allegations of kratom-associated adverse health effects, primarily based on case reports/series, have obtained media attention. Thus, a systematic literature search using PubMed was conducted to identify patterns among cases involving kratom use and acute adverse health effects in humans. 95 patients were identified for review. Mitragynine presence was toxicologically confirmed in 55 cases; 35 were deceased (mitragynine blood levels ranged from 3.5 to 7,500 ng/mL), and 20 were living (range of 5 to 340 ng/mL). Reported adverse effects included pulmonary, cardiovascular, brain, liver, kidney, and gastrointestinal effects, as well as seizures, loss of consciousness, lethargy, fatigue, and altered mental state. Toxicology panels revealed confounding substances that could have caused or contributed to the acute adverse effects in 32 deceased and seven surviving cases (p = 0.0002), despite attribution of many adverse effects solely to kratom. Upon analysis of the identified case reports, a pattern of weak or inadequate toxicology testing and medical history was observed. Currently, the literature provides insufficient evidence to support the claim that kratom consumption alone increases the risk of severe acute adverse health effects. More research is necessary to isolate the effects of kratom from those of polypharmacy.
通常被称为 kratom 的植物,因其具有刺激和止痛作用而在美国受到欢迎。主要基于病例报告/系列研究的关于 kratom 相关不良健康影响的指控引起了媒体关注。因此,利用 PubMed 进行了系统的文献检索,以确定涉及 kratom 使用及人类急性不良健康影响的病例中的模式。共确定了95名患者进行审查。在55例病例中经毒理学确认存在帽柱木碱;35例已死亡(帽柱木碱血药浓度范围为3.5至7500 ng/mL),20例存活(范围为5至340 ng/mL)。报告的不良反应包括肺部、心血管、脑部、肝脏、肾脏和胃肠道方面的影响,以及癫痫发作、意识丧失、嗜睡、疲劳和精神状态改变。毒理学检测显示,在32例死亡病例和7例存活病例中存在可能导致或促成急性不良反应的混杂物质(p = 0.0002),尽管许多不良反应仅归因于kratom。在对已识别的病例报告进行分析时,观察到毒理学检测和病史记录存在薄弱或不充分的模式。目前,文献提供的证据不足以支持仅服用kratom会增加严重急性不良健康影响风险这一说法。需要更多研究来区分kratom的影响与多药合用的影响。